Cargando…

The Immune Response to the fVIII Gene Therapy in Preclinical Models

Neutralizing antibodies to factor VIII (fVIII), referred to as “inhibitors,” remain the most challenging complication post-fVIII replacement therapy. Preclinical development of novel fVIII products involves studies incorporating hemophilia A (HA) and wild-type animal models. Though immunogenicity is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Seema R., Lundgren, Taran S., Spencer, H. Trent, Doering, Christopher B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174743/ https://www.ncbi.nlm.nih.gov/pubmed/32351497 http://dx.doi.org/10.3389/fimmu.2020.00494

Ejemplares similares

Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice
por: Lundgren, Taran S., et al.
Publicado: (2022)

Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
por: Zerra, Patricia E., et al.
Publicado: (2020)

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII
por: Ramamurthy, Ritu M., et al.
Publicado: (2022)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
por: Lytle, Allison M, et al.
Publicado: (2016)

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII
por: Russell, Athena L., et al.
Publicado: (2021)

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway
por: Patel, Seema R., et al.
Publicado: (2022)

Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies
por: Lacroix-Desmazes, Sébastien, et al.
Publicado: (2021)

Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
por: Peyvandi, Flora, et al.
Publicado: (2021)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
por: Cai, Yuanhua, et al.
Publicado: (2020)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
por: Rodriguez, Martin, et al.
Publicado: (2023)

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A
por: Johnston, Jennifer M., et al.
Publicado: (2012)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
por: El-Akabawy, Nadia, et al.
Publicado: (2020)

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor
por: Ronayne, Estelle K., et al.
Publicado: (2021)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
por: Lubich, Christian, et al.
Publicado: (2022)

Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
por: Batsuli, Glaivy, et al.
Publicado: (2023)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels
por: Trevisan, Brady, et al.
Publicado: (2022)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Macrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice—Brief Report
por: Ward, Soracha E., et al.
Publicado: (2023)

B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin
por: Biswas, Moanaro, et al.
Publicado: (2020)

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4(+) T-effector responses to multiple epitopes in FVIII
por: Gunasekera, Devi, et al.
Publicado: (2023)

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020)

Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1
por: Matino, Davide, et al.
Publicado: (2020)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
por: Chen, Alex C., et al.
Publicado: (2020)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

Association of Genetic Variant FVIII Gene and Factor VIII: A Pilot Study Among Hemophilia A Female Relatives in Saudi Arabia
por: Almohammadi, Abdullah T, et al.
Publicado: (2023)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec
por: Zhang, Lening, et al.
Publicado: (2019)

Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells
por: Pohl, Alessandra De Paula, et al.
Publicado: (2020)

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A
por: Stem, Christopher, et al.
Publicado: (2021)

Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood
por: Zhang, Lening, et al.
Publicado: (2022)

Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice
por: Liu, Chao Lien, et al.
Publicado: (2014)

Removal of Mannose-Ending Glycan at Asn(2118) Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells
por: Delignat, Sandrine, et al.
Publicado: (2020)

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
por: Bravo, M I, et al.
Publicado: (2014)

Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Editorial: Imaging the immune response in inflammatory preclinical in vivo models
por: Erreni, M., et al.
Publicado: (2023)

Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa
por: Kannicht, Christoph, et al.
Publicado: (2020)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
por: Brown, Harrison C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v2aidglcifutc52k3lktni669u